Celldex

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celldex and other ETFs, options, and stocks.

About CLDX

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. 

CEO
Anthony S. Marucci
CEOAnthony S. Marucci
Employees
198
Employees198
Headquarters
Hampton, New Jersey
HeadquartersHampton, New Jersey
Founded
1983
Founded1983
Employees
198
Employees198

CLDX Key Statistics

Market cap
2.44B
Market cap2.44B
Price-Earnings ratio
-7.14
Price-Earnings ratio-7.14
Dividend yield
—
Dividend yield—
Average volume
2.80M
Average volume2.80M
High today
$31.80
High today$31.80
Low today
$30.65
Low today$30.65
Open price
$31.44
Open price$31.44
Volume
2.02M
Volume2.02M
52 Week high
$45.14
52 Week high$45.14
52 Week low
$22.10
52 Week low$22.10

Stock Snapshot

As of today, Celldex(CLDX) shares are valued at $31.55. The company's market cap stands at 2.44B, with a P/E ratio of -7.14.

During the trading session on 2026-09-26, Celldex(CLDX) shares reached a daily high of $31.80 and a low of $30.65. At a current price of $31.55, the stock is +2.9% higher than the low and still -0.8% under the high.

Trading activity shows a volume of 2.02M, compared to an average daily volume of 2.8M.

The stock's 52-week range extends from a low of $22.10 to a high of $45.14.

The stock's 52-week range extends from a low of $22.10 to a high of $45.14.

CLDX News

Simply Wall St 2d
Is Celldex Therapeutics Fully Priced After Its Phase 3 Win?

has seen sharp swings in its share price over recent years, and fresh clinical news has pushed the story back into focus. The question now is whether the curren...

Is Celldex Therapeutics Fully Priced After Its Phase 3 Win?
TipRanks 4d
Celldex falls -11.4%

Celldex (CLDX) is down -11.4%, or -$4.31 to $33.58. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try N...

Seeking Alpha 4d
Celldex falls after late-stage trial data for hives therapy

Celldex (CLDX) lost more than 20% in the premarket on Tuesday even after announcing positive outcomes in two late-stage trials testing barzolvolimab, its experi...

Celldex falls after late-stage trial data for hives therapy

Analyst ratings

93%

of 15 ratings
Buy
93.3%
Hold
6.7%
Sell
0%

More CLDX News

TipRanks 4d
Celldex reports strong Phase 3 data in urticaria

An update from Celldex ( (CLDX) ) is now available. On September 22, 2026, Celldex reported positive topline data from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2...

TipRanks 4d
Celldex’s barzolvolimab meets endpoints in Phase 3 urticaria trial

Celldex (CLDX) reported positive topline results from the company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients...

People also own

Based on the portfolios of people who own CLDX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.